The financials
Xencor, Inc. by the numbers
Xencor, Inc. (XNCR) reported revenue of $4.5M in Q1 2026 (quarter ended March 31, 2026), down 86% from the same quarter a year earlier. That came with net loss of $129M. For the full year FY2025, revenue was $126M (+14% year on year) and net income −$92M. Its largest product in 2026-Q1 was Royalty at $4.4M, 98% of the disclosed total, just ahead of License at 2.2%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $4.5M | $33M | −86% |
| Operating income | −$78M | −$43M | n/a |
| Net income | −$129M | −$48M | n/a |
| Diluted EPS | −$1.71 | −$0.66 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Royalty | $4.4M | 98% |
| License | $100K | 2.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $4.5M (-78%)
Royalty grew -76% year on yearMilestone -100% year on year
Segment Latestquarter on quarteryear on year
- Royalty$4.4M$4.4MQoQ -79%year on year -76%-79%-76%
- License$100.0K$100.0KQoQ -year on year ---
- Milestone$0.00$0.00QoQ -year on year -100%--100%
Biotechnology
The closest names by size in the same industry